COMPLETE TEST BANK FOR
PHARMACOLOGY: A PATIENT-CENTERED NURSING
PROCESS APPROACH 10TH EDITION
BY LINDA E. MCCUISTION|CHAPTERS 1-55|CORRECT ANSWERS
,TABLE OF CONTENTS
CHAPTER 01:THE NURSING PROCESS AND PATIENT-CENTERED CARE ....................................................... 4
CHAPTER 02: DRUG DEVELOPMENT AND ETHICAL CONSIDERATIONS ..................................................... 11
CHAPTER 03: PHARMACOKINETICS, PHARMACODYNAMICS, AND PHARMACOGENETICS ..................... 22
CHAPTER 04: PHARMACOGENETICS .......................................................................................................... 42
CHAPTER 05: COMPLEMENTARY AND ALTERNATIVE THERAPIES............................................................. 46
CHAPTER 06: PEDIATRIC CONSIDERATIONS .............................................................................................. 53
CHAPTER 07: GERIATRIC CONSIDERATIONS .............................................................................................. 61
CHAPTER 08: DRUGS OF ABUSE ................................................................................................................. 68
CHAPTER 09: SAFETY AND QUALITY .......................................................................................................... 75
CHAPTER 10: DRUG ADMINISTRATION ..................................................................................................... 83
CHAPTER 11: DRUG CALCULATIONS ........................................................................................................... 90
CHAPTER 12: FLUID VOLUME AND ELECTROLYTES ..................................................................................... 96
CHAPTER 13: VITAMIN AND MINERAL REPLACEMENT ............................................................................. 107
CHAPTER 14: NUTRITIONAL SUPPORT ...................................................................................................... 116
CHAPTER 15: ADRENERGIC AGONISTS AND ANTAGONISTS ..................................................................... 126
CHAPTER 16: CHOLINERGIC AGONISTS AND ANTAGONISTS .................................................................... 134
CHAPTER 17: STIMULANTS ....................................................................................................................... 142
CHAPTER 18: DEPRESSANTS...................................................................................................................... 148
CHAPTER 19: ANTISEIZURE DRUGS ........................................................................................................... 156
CHAPTER 20: DRUGS FOR PARKINSON DISEASE AND ALZHEIMER DISEASE ............................................. 165
CHAPTER 21: DRUGS FOR NEUROMUSCULAR DISORDERS AND MUSCLE SPASMS .................................. 174
CHAPTER 22: ANTIPSYCHOTICS AND ANXIOLYTICS .................................................................................. 182
CHAPTER 23: ANTIDEPRESSANTS AND MOOD STABILIZERS ..................................................................... 192
CHAPTER 24: ANTIINFLAMMATORIES....................................................................................................... 201
CHAPTER 25: ANALGESICS ........................................................................................................................ 210
CHAPTER 26: ANTIBACTERIALS ................................................................................................................. 218
CHAPTER 27: ANTITUBERCULARS, ANTIFUNGALS, AND ANTIVIRALS ....................................................... 241
CHAPTER 28: PEPTIDES, ANTIMALARIALS, AND ANTHELMINTICS ............................................................ 252
CHAPTER 29: HIV- AND AIDS-RELATED DRUGS ......................................................................................... 256
CHAPTER 30: TRANSPLANT DRUGS ........................................................................................................... 261
CHAPTER 31: VACCINES ............................................................................................................................ 265
CHAPTER 32: ANTICANCER DRUGS ........................................................................................................... 270
,CHAPTER 33: TARGETED THERAPIES TO TREAT CANCER .......................................................................... 276
CHAPTER 34: BIOLOGIC RESPONSE MODIFIERS ........................................................................................ 280
CHAPTER 35: UPPER RESPIRATORY DISORDERS ....................................................................................... 286
CHAPTER 36: LOWER RESPIRATORY DISORDERS ...................................................................................... 291
CHAPTER 37: CARDIAC GLYCOSIDES, ANTIANGINALS, AND ANTIDYSRHYTHMICS ................................... 299
CHAPTER 38: DIURETICS ........................................................................................................................... 309
CHAPTER 39: ANTIHYPERTENSIVES ........................................................................................................... 315
CHAPTER 40: ANTICOAGULANTS, ANTIPLATELETS, AND THROMBOLYTICS ............................................. 322
CHAPTER 41: ANTIHYPERLIPIDEMICS AND PERIPHERAL VASODILATORS ................................................. 331
CHAPTER 42: GASTROINTESTINAL TRACT DISORDERS.............................................................................. 338
CHAPTER 43: ANTIULCER DRUGS .............................................................................................................. 346
CHAPTER 44: EYE AND EAR DISORDERS .................................................................................................... 354
CHAPTER 45: DERMATOLOGIC DISORDERS .............................................................................................. 359
CHAPTER 46: PITUITARY, THYROID, PARATHYROID, AND ADRENAL DISORDERS ..................................... 365
CHAPTER 47: ANTIDIABETICS .................................................................................................................... 374
CHAPTER 48: URINARY DISORDERS .......................................................................................................... 382
CHAPTER 49: PREGNANCY AND PRETERM LABOR .................................................................................... 389
CHAPTER 50: LABOR, DELIVERY, AND POSTPARTUM ............................................................................... 397
CHAPTER 51: NEONATAL AND NEWBORN ................................................................................................ 403
CHAPTER 52: WOMEN’S REPRODUCTIVE HEALTH .................................................................................... 405
CHAPTER 53: MEN’S REPRODUCTIVE HEALTH .......................................................................................... 414
CHAPTER 54: SEXUALLY TRANSMITTED INFECTIONS ................................................................................ 419
CHAPTER 55: ADULT AND PEDIATRIC EMERGENCY DRUGS...................................................................... 422
,CHAPTER 01:THE NURSING PROCESS AND PATIENT-CENTERED CARE
MCCUISTION: PHARMACOLOGY: A PATIENT-CENTERED NURSING PROCESS
APPROACH, 10TH EDITION
MULTIPLE CHOICE
1. THE NURSING PROCESS IS A FIVE-STEP DECISION-MAKING APPROACH THAT INCLUDES ALL OF
THE FOLLOWING STEPS, EXCEPT:
A. ASSESSMENT
B. PATIENT PROBLEM
C. PLANNING
D. RIGHT DRUG
ANS: D
THE NURSING PROCESS IS A FIVE-STEP DECISION-MAKING APPROACH THAT INCLUDES: 1) ASSESSMENT,
2) PATIENT PROBLEM, 3) PLANNING, 4) IMPLEMENTATION, AND 5) EVALUATION. “RIGHT DRUG” IS ONE
OF THE “SIX RIGHTS” OF MEDICATION ADMINISTRATION.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS:
PLANNING MSC: NCLEX: MANAGEMENT OF CARE
2. THE NURSE IS USING DATA COLLECTED TO SET GOALS OR EXPECTED OUTCOMES AND
INTERVENTIONS THAT ADDRESS THE PATIENT’S PROBLEMS. WHICH STEP OF THE NURSING PROCESS IS
THE NURSE APPLYING?
A. ASSESSMENT
B. PATIENT PROBLEM
C. PLANNING
D. EVALUATION
ANS: C
DURING THE PLANNING PHASE, THE NURSE USES THE DATA COLLECTED TO SET GOALS OR EXPECTED
OUTCOMES AND INTERVENTIONS WHICH ADDRESS THE PATIENT’S PROBLEMS. THE DATA WAS
COLLECTED DURING THE “ASSESSMENT” AND “PATIENT PROBLEM” STEPS. DURING THE “EVALUATION”
PHASE THE NURSE WOULD DETERMINE WHETHER THE GOALS AND OBJECTIVES SET DURING THE
PLANNING PHASE WERE MET.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS: NURSING
INTERVENTION
MSC: NCLEX: MANAGEMENT OF CARE
,3. A 5-YEAR-OLD CHILD WITH TYPE 1 DIABETES MELLITUS HAS HAD REPEATED HOSPITALIZATIONS
FOR EPISODES OF HYPERGLYCEMIA. THE PARENTS TELL THE NURSE THAT THEY CAN’T KEEP TRACK OF
EVERYTHING THAT HAS TO BE DONE TO CARE FOR THEIR CHILD. THE NURSE REVIEWS MEDICATIONS,
DIET, AND SYMPTOM MANAGEMENT WITH THE PARENTS AND DRAWS UP A DAILY CHECKLIST FOR THE
FAMILY TO USE. THESE ACTIVITIES ARE COMPLETED IN WHICH STEP OF THE NURSING PROCESS?
A. ASSESSMENT
B. PLANNING
C. IMPLEMENTATION
D. EVALUATION
ANS: C
THE IMPLEMENTATION PHASE IS THE PART OF THE NURSING PROCESS IN WHICH THE NURSE PROVIDES
EDUCATION, DRUG ADMINISTRATION, PATIENT CARE, AND OTHER INTERVENTIONS NECESSARY TO
ASSIST THE PATIENT IN ACCOMPLISHING ESTABLISHED MEDICATION GOALS.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS: NURSING
INTERVENTION
MSC: NCLEX: MANAGEMENT OF CARE
4. THE NURSE IS PREPARING TO ADMINISTER A MEDICATION AND REVIEWS THE PATIENT’S CHART
FOR DRUG ALLERGIES, SERUM CREATININE, AND BLOOD UREA NITROGEN (BUN) LEVELS. THE NURSE’S
ACTIONS ARE REFLECTIVE OF WHICH PHASE OF THE NURSING PROCESS?
A. ASSESSMENT
B. EVALUATION
C. IMPLEMENTATION
D. PLANNING
ANS: A
ASSESSMENT INVOLVES GATHERING INFORMATION ABOUT THE PATIENT AND THE DRUG, INCLUDING
ANY PREVIOUS USE OF THE DRUG.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION)
TOP: NURSING PROCESS: ASSESSMENT MSC: NCLEX: MANAGEMENT OF CARE
5. WHICH ASSESSMENT IS CATEGORIZED AS OBJECTIVE DATA?
,A. A LIST OF HERBAL SUPPLEMENTS REGULARLY USED
B. LAB VALUES ASSOCIATED WITH THE DRUGS THE PATIENT IS TAKING
C. THE AGES AND RELATIONSHIP TO THE PATIENT OF ALL HOUSEHOLD MEMBERS
D. USUAL DIETARY PATTERNS AND FNOOD INTAKE
ANS: B
OBJECTIVE DATA ARE MEASURED AND DETECTED BY ANOTHER PERSON AND WOULD INCLUDE LAB
VALUES. THE OTHER EXAMPLES ARE SUBJECTIVE DATA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION)
TOP: NURSING PROCESS: ASSESSMENT MSC: NCLEX: MANAGEMENT OF CARE
6. THE NURSE REVIEWS A PATIENT’S DATABASE AND LEARNS THAT THE PATIENT LIVES ALONE, IS
FORGETFUL, AND DOES NOT HAVE AN ESTABLISHED ROUTINE. THE PATIENT WILL BE SENT HOME WITH
THREE NEW MEDICATIONS TO BE TAKEN AT DIFFERENT TIMES OF THE DAY. THE NURSE DEVELOPS A
DAILY MEDICATION CHART AND ENLISTS A FAMILY MEMBER TO PUT THE PATIENT’S PILLS IN A PILL
ORGANIZER. THIS IS AN EXAMPLE OF WHICH PHASE OF THE NURSING PROCESS?
A. ASSESSMENT
B. EVALUATION
C. IMPLEMENTATION
D. PLANNING
ANS: C
THE IMPLEMENTATION PHASE INVOLVES EDUCATION AND PATIENT CARE IN ORDER TO ASSIST THE
PATIENT TO
ACCOMPLISH THE GOALS OF TREATMENT.
DIF: COGNITIVE LEVEL: APPLYING (APPLICATION) TOP: NURSING PROCESS: NURSING INTERVENTION
MSC: NCLEX: MANAGEMENT OF CARE
7. A PATIENT WHO IS HOSPITALIZED FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
WANTS TO GO HOME. THE NURSE AND THE PATIENT DISCUSS THE PATIENT’S SITUATION AND DECIDE
THAT THE PATIENT MAY GO HOME WHEN ABLE TO PERFORM SELF-CARE WITHOUT DYSPNEA AND
HYPOXIA. THIS IS AN EXAMPLE OF WHICH PHASE OF THE NURSING PROCESS?
A. ASSESSMENT
B. EVALUATION
C. IMPLEMENTATION
, D. PLANNING
ANS: D
PLANNING INVOLVES GOAL SETTING, WHICH, FOR THIS PATIENT, MEANS BEING ABLE TO PERFORM
SELF-CARE ACTIVITIES WITHOUT DYSPNEA AND HYPOXIA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS:
PLANNING MSC: NCLEX: MANAGEMENT OF CARE
8. A PATIENT WILL BE SENT HOME WITH A METERED-DOSE INHALER, AND THE NURSE IS
PROVIDING TEACHING. WHICH IS A CORRECTLY WRITTEN GOAL FOR THIS PROCESS?
A. THE NURSE WILL DEMONSTRATE THE CORRECT USE OF A METERED-DOSE INHALER TO THE
PATIENT.
B. THE NURSE WILL TEACH THE PATIENT HOW TO ADMINISTER MEDICATION WITH A METERED-
DOSE INHALER.
C. THE PATIENT WILL KNOW HOW TO SELF-ADMINISTER THE MEDICATION USING THE METERED-
DOSE INHALER.
D. THE PATIENT WILL INDEPENDENTLY ADMINISTER THE MEDICATION USING THE METERED-DOSE
INHALER AT THE END OF THE SESSION.
ANS: D
GOALS MUST BE PATIENT-CENTERED AND CLEARLY STATE THE OUTCOME WITH A REASONABLE
DEADLINE AND SHOULD IDENTIFY COMPONENTS FOR EVALUATION.
DIF: COGNITIVE LEVEL: APPLYING (APPLICATION) TOP: NURSING PROCESS: PLANNING MSC:
NCLEX: MANAGEMENT OF CARE
9. THE NURSE IS DEVELOPING A PLAN OF CARE FOR A PATIENT WHO HAS CHRONIC LUNG DISEASE
AND HYPOXIA. THE PATIENT HAS BEEN ADMITTED FOR INCREASED OXYGEN NEEDS ABOVE A BASELINE
OF 2 L/MIN. THE NURSE DEVELOPS A GOAL STATING, “THE PATIENT WILL HAVE OXYGEN SATURATIONS
OF >95% ON ROOM AIR AT THE TIME OF DISCHARGE FROM THE HOSPITAL.” WHAT IS WRONG WITH
THIS GOAL?
A. IT CANNOT BE EVALUATED.
B. IT IS NOT MEASURABLE.
C. IT IS NOT PATIENT-CENTERED.
D. IT IS NOT REALISTIC.
PHARMACOLOGY: A PATIENT-CENTERED NURSING
PROCESS APPROACH 10TH EDITION
BY LINDA E. MCCUISTION|CHAPTERS 1-55|CORRECT ANSWERS
,TABLE OF CONTENTS
CHAPTER 01:THE NURSING PROCESS AND PATIENT-CENTERED CARE ....................................................... 4
CHAPTER 02: DRUG DEVELOPMENT AND ETHICAL CONSIDERATIONS ..................................................... 11
CHAPTER 03: PHARMACOKINETICS, PHARMACODYNAMICS, AND PHARMACOGENETICS ..................... 22
CHAPTER 04: PHARMACOGENETICS .......................................................................................................... 42
CHAPTER 05: COMPLEMENTARY AND ALTERNATIVE THERAPIES............................................................. 46
CHAPTER 06: PEDIATRIC CONSIDERATIONS .............................................................................................. 53
CHAPTER 07: GERIATRIC CONSIDERATIONS .............................................................................................. 61
CHAPTER 08: DRUGS OF ABUSE ................................................................................................................. 68
CHAPTER 09: SAFETY AND QUALITY .......................................................................................................... 75
CHAPTER 10: DRUG ADMINISTRATION ..................................................................................................... 83
CHAPTER 11: DRUG CALCULATIONS ........................................................................................................... 90
CHAPTER 12: FLUID VOLUME AND ELECTROLYTES ..................................................................................... 96
CHAPTER 13: VITAMIN AND MINERAL REPLACEMENT ............................................................................. 107
CHAPTER 14: NUTRITIONAL SUPPORT ...................................................................................................... 116
CHAPTER 15: ADRENERGIC AGONISTS AND ANTAGONISTS ..................................................................... 126
CHAPTER 16: CHOLINERGIC AGONISTS AND ANTAGONISTS .................................................................... 134
CHAPTER 17: STIMULANTS ....................................................................................................................... 142
CHAPTER 18: DEPRESSANTS...................................................................................................................... 148
CHAPTER 19: ANTISEIZURE DRUGS ........................................................................................................... 156
CHAPTER 20: DRUGS FOR PARKINSON DISEASE AND ALZHEIMER DISEASE ............................................. 165
CHAPTER 21: DRUGS FOR NEUROMUSCULAR DISORDERS AND MUSCLE SPASMS .................................. 174
CHAPTER 22: ANTIPSYCHOTICS AND ANXIOLYTICS .................................................................................. 182
CHAPTER 23: ANTIDEPRESSANTS AND MOOD STABILIZERS ..................................................................... 192
CHAPTER 24: ANTIINFLAMMATORIES....................................................................................................... 201
CHAPTER 25: ANALGESICS ........................................................................................................................ 210
CHAPTER 26: ANTIBACTERIALS ................................................................................................................. 218
CHAPTER 27: ANTITUBERCULARS, ANTIFUNGALS, AND ANTIVIRALS ....................................................... 241
CHAPTER 28: PEPTIDES, ANTIMALARIALS, AND ANTHELMINTICS ............................................................ 252
CHAPTER 29: HIV- AND AIDS-RELATED DRUGS ......................................................................................... 256
CHAPTER 30: TRANSPLANT DRUGS ........................................................................................................... 261
CHAPTER 31: VACCINES ............................................................................................................................ 265
CHAPTER 32: ANTICANCER DRUGS ........................................................................................................... 270
,CHAPTER 33: TARGETED THERAPIES TO TREAT CANCER .......................................................................... 276
CHAPTER 34: BIOLOGIC RESPONSE MODIFIERS ........................................................................................ 280
CHAPTER 35: UPPER RESPIRATORY DISORDERS ....................................................................................... 286
CHAPTER 36: LOWER RESPIRATORY DISORDERS ...................................................................................... 291
CHAPTER 37: CARDIAC GLYCOSIDES, ANTIANGINALS, AND ANTIDYSRHYTHMICS ................................... 299
CHAPTER 38: DIURETICS ........................................................................................................................... 309
CHAPTER 39: ANTIHYPERTENSIVES ........................................................................................................... 315
CHAPTER 40: ANTICOAGULANTS, ANTIPLATELETS, AND THROMBOLYTICS ............................................. 322
CHAPTER 41: ANTIHYPERLIPIDEMICS AND PERIPHERAL VASODILATORS ................................................. 331
CHAPTER 42: GASTROINTESTINAL TRACT DISORDERS.............................................................................. 338
CHAPTER 43: ANTIULCER DRUGS .............................................................................................................. 346
CHAPTER 44: EYE AND EAR DISORDERS .................................................................................................... 354
CHAPTER 45: DERMATOLOGIC DISORDERS .............................................................................................. 359
CHAPTER 46: PITUITARY, THYROID, PARATHYROID, AND ADRENAL DISORDERS ..................................... 365
CHAPTER 47: ANTIDIABETICS .................................................................................................................... 374
CHAPTER 48: URINARY DISORDERS .......................................................................................................... 382
CHAPTER 49: PREGNANCY AND PRETERM LABOR .................................................................................... 389
CHAPTER 50: LABOR, DELIVERY, AND POSTPARTUM ............................................................................... 397
CHAPTER 51: NEONATAL AND NEWBORN ................................................................................................ 403
CHAPTER 52: WOMEN’S REPRODUCTIVE HEALTH .................................................................................... 405
CHAPTER 53: MEN’S REPRODUCTIVE HEALTH .......................................................................................... 414
CHAPTER 54: SEXUALLY TRANSMITTED INFECTIONS ................................................................................ 419
CHAPTER 55: ADULT AND PEDIATRIC EMERGENCY DRUGS...................................................................... 422
,CHAPTER 01:THE NURSING PROCESS AND PATIENT-CENTERED CARE
MCCUISTION: PHARMACOLOGY: A PATIENT-CENTERED NURSING PROCESS
APPROACH, 10TH EDITION
MULTIPLE CHOICE
1. THE NURSING PROCESS IS A FIVE-STEP DECISION-MAKING APPROACH THAT INCLUDES ALL OF
THE FOLLOWING STEPS, EXCEPT:
A. ASSESSMENT
B. PATIENT PROBLEM
C. PLANNING
D. RIGHT DRUG
ANS: D
THE NURSING PROCESS IS A FIVE-STEP DECISION-MAKING APPROACH THAT INCLUDES: 1) ASSESSMENT,
2) PATIENT PROBLEM, 3) PLANNING, 4) IMPLEMENTATION, AND 5) EVALUATION. “RIGHT DRUG” IS ONE
OF THE “SIX RIGHTS” OF MEDICATION ADMINISTRATION.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS:
PLANNING MSC: NCLEX: MANAGEMENT OF CARE
2. THE NURSE IS USING DATA COLLECTED TO SET GOALS OR EXPECTED OUTCOMES AND
INTERVENTIONS THAT ADDRESS THE PATIENT’S PROBLEMS. WHICH STEP OF THE NURSING PROCESS IS
THE NURSE APPLYING?
A. ASSESSMENT
B. PATIENT PROBLEM
C. PLANNING
D. EVALUATION
ANS: C
DURING THE PLANNING PHASE, THE NURSE USES THE DATA COLLECTED TO SET GOALS OR EXPECTED
OUTCOMES AND INTERVENTIONS WHICH ADDRESS THE PATIENT’S PROBLEMS. THE DATA WAS
COLLECTED DURING THE “ASSESSMENT” AND “PATIENT PROBLEM” STEPS. DURING THE “EVALUATION”
PHASE THE NURSE WOULD DETERMINE WHETHER THE GOALS AND OBJECTIVES SET DURING THE
PLANNING PHASE WERE MET.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS: NURSING
INTERVENTION
MSC: NCLEX: MANAGEMENT OF CARE
,3. A 5-YEAR-OLD CHILD WITH TYPE 1 DIABETES MELLITUS HAS HAD REPEATED HOSPITALIZATIONS
FOR EPISODES OF HYPERGLYCEMIA. THE PARENTS TELL THE NURSE THAT THEY CAN’T KEEP TRACK OF
EVERYTHING THAT HAS TO BE DONE TO CARE FOR THEIR CHILD. THE NURSE REVIEWS MEDICATIONS,
DIET, AND SYMPTOM MANAGEMENT WITH THE PARENTS AND DRAWS UP A DAILY CHECKLIST FOR THE
FAMILY TO USE. THESE ACTIVITIES ARE COMPLETED IN WHICH STEP OF THE NURSING PROCESS?
A. ASSESSMENT
B. PLANNING
C. IMPLEMENTATION
D. EVALUATION
ANS: C
THE IMPLEMENTATION PHASE IS THE PART OF THE NURSING PROCESS IN WHICH THE NURSE PROVIDES
EDUCATION, DRUG ADMINISTRATION, PATIENT CARE, AND OTHER INTERVENTIONS NECESSARY TO
ASSIST THE PATIENT IN ACCOMPLISHING ESTABLISHED MEDICATION GOALS.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS: NURSING
INTERVENTION
MSC: NCLEX: MANAGEMENT OF CARE
4. THE NURSE IS PREPARING TO ADMINISTER A MEDICATION AND REVIEWS THE PATIENT’S CHART
FOR DRUG ALLERGIES, SERUM CREATININE, AND BLOOD UREA NITROGEN (BUN) LEVELS. THE NURSE’S
ACTIONS ARE REFLECTIVE OF WHICH PHASE OF THE NURSING PROCESS?
A. ASSESSMENT
B. EVALUATION
C. IMPLEMENTATION
D. PLANNING
ANS: A
ASSESSMENT INVOLVES GATHERING INFORMATION ABOUT THE PATIENT AND THE DRUG, INCLUDING
ANY PREVIOUS USE OF THE DRUG.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION)
TOP: NURSING PROCESS: ASSESSMENT MSC: NCLEX: MANAGEMENT OF CARE
5. WHICH ASSESSMENT IS CATEGORIZED AS OBJECTIVE DATA?
,A. A LIST OF HERBAL SUPPLEMENTS REGULARLY USED
B. LAB VALUES ASSOCIATED WITH THE DRUGS THE PATIENT IS TAKING
C. THE AGES AND RELATIONSHIP TO THE PATIENT OF ALL HOUSEHOLD MEMBERS
D. USUAL DIETARY PATTERNS AND FNOOD INTAKE
ANS: B
OBJECTIVE DATA ARE MEASURED AND DETECTED BY ANOTHER PERSON AND WOULD INCLUDE LAB
VALUES. THE OTHER EXAMPLES ARE SUBJECTIVE DATA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION)
TOP: NURSING PROCESS: ASSESSMENT MSC: NCLEX: MANAGEMENT OF CARE
6. THE NURSE REVIEWS A PATIENT’S DATABASE AND LEARNS THAT THE PATIENT LIVES ALONE, IS
FORGETFUL, AND DOES NOT HAVE AN ESTABLISHED ROUTINE. THE PATIENT WILL BE SENT HOME WITH
THREE NEW MEDICATIONS TO BE TAKEN AT DIFFERENT TIMES OF THE DAY. THE NURSE DEVELOPS A
DAILY MEDICATION CHART AND ENLISTS A FAMILY MEMBER TO PUT THE PATIENT’S PILLS IN A PILL
ORGANIZER. THIS IS AN EXAMPLE OF WHICH PHASE OF THE NURSING PROCESS?
A. ASSESSMENT
B. EVALUATION
C. IMPLEMENTATION
D. PLANNING
ANS: C
THE IMPLEMENTATION PHASE INVOLVES EDUCATION AND PATIENT CARE IN ORDER TO ASSIST THE
PATIENT TO
ACCOMPLISH THE GOALS OF TREATMENT.
DIF: COGNITIVE LEVEL: APPLYING (APPLICATION) TOP: NURSING PROCESS: NURSING INTERVENTION
MSC: NCLEX: MANAGEMENT OF CARE
7. A PATIENT WHO IS HOSPITALIZED FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
WANTS TO GO HOME. THE NURSE AND THE PATIENT DISCUSS THE PATIENT’S SITUATION AND DECIDE
THAT THE PATIENT MAY GO HOME WHEN ABLE TO PERFORM SELF-CARE WITHOUT DYSPNEA AND
HYPOXIA. THIS IS AN EXAMPLE OF WHICH PHASE OF THE NURSING PROCESS?
A. ASSESSMENT
B. EVALUATION
C. IMPLEMENTATION
, D. PLANNING
ANS: D
PLANNING INVOLVES GOAL SETTING, WHICH, FOR THIS PATIENT, MEANS BEING ABLE TO PERFORM
SELF-CARE ACTIVITIES WITHOUT DYSPNEA AND HYPOXIA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS:
PLANNING MSC: NCLEX: MANAGEMENT OF CARE
8. A PATIENT WILL BE SENT HOME WITH A METERED-DOSE INHALER, AND THE NURSE IS
PROVIDING TEACHING. WHICH IS A CORRECTLY WRITTEN GOAL FOR THIS PROCESS?
A. THE NURSE WILL DEMONSTRATE THE CORRECT USE OF A METERED-DOSE INHALER TO THE
PATIENT.
B. THE NURSE WILL TEACH THE PATIENT HOW TO ADMINISTER MEDICATION WITH A METERED-
DOSE INHALER.
C. THE PATIENT WILL KNOW HOW TO SELF-ADMINISTER THE MEDICATION USING THE METERED-
DOSE INHALER.
D. THE PATIENT WILL INDEPENDENTLY ADMINISTER THE MEDICATION USING THE METERED-DOSE
INHALER AT THE END OF THE SESSION.
ANS: D
GOALS MUST BE PATIENT-CENTERED AND CLEARLY STATE THE OUTCOME WITH A REASONABLE
DEADLINE AND SHOULD IDENTIFY COMPONENTS FOR EVALUATION.
DIF: COGNITIVE LEVEL: APPLYING (APPLICATION) TOP: NURSING PROCESS: PLANNING MSC:
NCLEX: MANAGEMENT OF CARE
9. THE NURSE IS DEVELOPING A PLAN OF CARE FOR A PATIENT WHO HAS CHRONIC LUNG DISEASE
AND HYPOXIA. THE PATIENT HAS BEEN ADMITTED FOR INCREASED OXYGEN NEEDS ABOVE A BASELINE
OF 2 L/MIN. THE NURSE DEVELOPS A GOAL STATING, “THE PATIENT WILL HAVE OXYGEN SATURATIONS
OF >95% ON ROOM AIR AT THE TIME OF DISCHARGE FROM THE HOSPITAL.” WHAT IS WRONG WITH
THIS GOAL?
A. IT CANNOT BE EVALUATED.
B. IT IS NOT MEASURABLE.
C. IT IS NOT PATIENT-CENTERED.
D. IT IS NOT REALISTIC.
